Skip to main content
Top
Published in: Hepatology International 2/2007

01-06-2007 | Original Paper

Interferon-beta is activated by hepatitis C virus NS5B and inhibited by NS4A, NS4B, and NS5A

Authors: Masaru Moriyama, Naoya Kato, Motoyuki Otsuka, Run-Xuan Shao, Hiroyoshi Taniguchi, Takao Kawabe, Masao Omata

Published in: Hepatology International | Issue 2/2007

Login to get access

Abstract

Innate immunity is part of the antiviral response. Interferon (IFN)-beta plays a leading role in this system. To investigate the influence of hepatitis C virus (HCV) on innate immunity, we examined the effect of viral proteins on IFN-beta induction. HepG2 cells were co-transfected with plasmids for seven HCV proteins (core protein, NS2, NS3, NS4A, NS4B, NS5A, and NS5B) and the IFN-beta promoter luciferase. Toll-like receptor (TLR) 3 and Toll/IL-1 receptor domain-containing adapter inducing IFN-beta (TRIF) play key roles in dsRNA-mediated activation of interferon regulatory factor (IRF)-3 and IFN-beta; therefore, the participation of TLR3/TRIF in NS5B-mediated IFN induction was examined. Among seven HCV proteins, only NS5B, a viral RNA-dependent RNA polymerase (RdRp), activated the IFN-beta promoter. However, mutant NS5B without RdRp activity or template/primer association did not activate the IFN-beta promoter. Activation of the IFN-beta promoter by NS5B required the positive regulatory domain III, a binding sequence for IRF-3. Moreover, IRF-3 was phosphorylated by NS5B. Both inhibition of TLR3 expression by small interfering RNA and expression of the dominant negative form of TRIF significantly reduced NS5B-induced activation of IFN-beta. Of the six other HCV proteins, NS4A, NS4B, and NS5A efficiently inhibited this activation. HCV NS5B is a potent activator of the host innate immune system, possibly through TLR3/TRIF and synthesis of dsRNA. Meanwhile, NS4A, NS4B, and NS5A block IFN-beta induction by NS5B, which may contribute toward the persistence of this virus.
Literature
1.
go back to reference Kuo G, Choo QL, Alter HJ, Gintick GL, Redeker AG, Purcell RH, et al. An assay for circulating antibodies to a major etiologic virus of human non-A non-B hepatitis. Science 1989;244:362–4.PubMedCrossRef Kuo G, Choo QL, Alter HJ, Gintick GL, Redeker AG, Purcell RH, et al. An assay for circulating antibodies to a major etiologic virus of human non-A non-B hepatitis. Science 1989;244:362–4.PubMedCrossRef
2.
go back to reference Saito M, Miyamura T, Ohbayashi A, Harada H, Katayama T, Kichi S, et al. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci USA 1990;87:6547–9.PubMedCrossRef Saito M, Miyamura T, Ohbayashi A, Harada H, Katayama T, Kichi S, et al. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci USA 1990;87:6547–9.PubMedCrossRef
3.
go back to reference Shiratori Y, Shiina S, Imamura M, Kato N, Kanai F, Okudaira T, et al. Characteristic difference of hepatocellular carcinoma between hepatitis B- and C- viral infection in Japan. Hepatology 1995;22:1027–33.PubMedCrossRef Shiratori Y, Shiina S, Imamura M, Kato N, Kanai F, Okudaira T, et al. Characteristic difference of hepatocellular carcinoma between hepatitis B- and C- viral infection in Japan. Hepatology 1995;22:1027–33.PubMedCrossRef
4.
go back to reference Choo QL, Richman KH, Han JH, Berger K, Lee C, Dong C, et al. Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci USA 1991;88:2451–5.PubMedCrossRef Choo QL, Richman KH, Han JH, Berger K, Lee C, Dong C, et al. Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci USA 1991;88:2451–5.PubMedCrossRef
5.
go back to reference Hijikata M, Kato N, Ootsuyama Y, Nakagawa M, Shimotohno K. Gene mapping of the putative structural region of the hepatitis C virus genome by in vitro processing analysis. Proc Natl Acad Sci USA 1991;88:5547–51.PubMedCrossRef Hijikata M, Kato N, Ootsuyama Y, Nakagawa M, Shimotohno K. Gene mapping of the putative structural region of the hepatitis C virus genome by in vitro processing analysis. Proc Natl Acad Sci USA 1991;88:5547–51.PubMedCrossRef
6.
go back to reference Poch O, Sauvaget I, Delarue M, Tordo N. Identification of four conserved motifs among the RNA-dependent RNA polymerase of hepatitis C virus. EMBO J 1989;8:3867–74.PubMed Poch O, Sauvaget I, Delarue M, Tordo N. Identification of four conserved motifs among the RNA-dependent RNA polymerase of hepatitis C virus. EMBO J 1989;8:3867–74.PubMed
7.
go back to reference Behrens SE, Tomei L, De Francesco R. Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus. EMBO J 1996;15:12–22.PubMed Behrens SE, Tomei L, De Francesco R. Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus. EMBO J 1996;15:12–22.PubMed
8.
go back to reference Du W, Maniatis T. An ATF/CREB binding site protein is required for virus induction of the human interferon-beta gene. Proc Natl Acad Sci USA 1992;89:2150–4.PubMedCrossRef Du W, Maniatis T. An ATF/CREB binding site protein is required for virus induction of the human interferon-beta gene. Proc Natl Acad Sci USA 1992;89:2150–4.PubMedCrossRef
9.
go back to reference Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001;2:675.PubMedCrossRef Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001;2:675.PubMedCrossRef
10.
go back to reference Fitzgerald KA, Palsson-McDermott EM, Bowie AG, Jefferies C, Mansell AS, Brady G et al. Mal (MyD88-adaptor like) is required for Toll-like receptor-4 signal transduction. Nature 2001;413:78.PubMedCrossRef Fitzgerald KA, Palsson-McDermott EM, Bowie AG, Jefferies C, Mansell AS, Brady G et al. Mal (MyD88-adaptor like) is required for Toll-like receptor-4 signal transduction. Nature 2001;413:78.PubMedCrossRef
11.
go back to reference Yamamoto M, Sato S, Mori K, Hoshino K, Takeuchi O, Takeda K, et al. A novel toll/IL-1 receptor domain-containing adaptor that preferentially activates the IFN-beta promoter in the toll-like receptor signaling. J Immunol 2002;169:6669–72. Yamamoto M, Sato S, Mori K, Hoshino K, Takeuchi O, Takeda K, et al. A novel toll/IL-1 receptor domain-containing adaptor that preferentially activates the IFN-beta promoter in the toll-like receptor signaling. J Immunol 2002;169:6669–72.
12.
go back to reference Oshiumi H, Matsumoto M, Funami K, Akazawa T, Seya T. TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon-beta induction. Nature Immunol 2003;4:161–7.CrossRef Oshiumi H, Matsumoto M, Funami K, Akazawa T, Seya T. TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon-beta induction. Nature Immunol 2003;4:161–7.CrossRef
13.
go back to reference Suhara W, Yoneyama M, Iwamura T, Yoshimura S, Tamura K, Namiki H, et al. Analysis of virus-induced homomeric and heteromeric protein associations between IRF-3 and coactivator CBP/p300. J Biochem 2000;128:301–7.PubMed Suhara W, Yoneyama M, Iwamura T, Yoshimura S, Tamura K, Namiki H, et al. Analysis of virus-induced homomeric and heteromeric protein associations between IRF-3 and coactivator CBP/p300. J Biochem 2000;128:301–7.PubMed
14.
go back to reference Yoneyama M, Suhara W, Fukuhara Y, Fukuda M, Nishida E, Fujita T. Direct triggering of the type I interferon system by virus infection: activation of transcription factor complex containing IRF-3 and CBP/p300. EMBO J 1998;17:1087–95.PubMedCrossRef Yoneyama M, Suhara W, Fukuhara Y, Fukuda M, Nishida E, Fujita T. Direct triggering of the type I interferon system by virus infection: activation of transcription factor complex containing IRF-3 and CBP/p300. EMBO J 1998;17:1087–95.PubMedCrossRef
15.
go back to reference Servant MJ, ten Oever B, LePage C, Conti L, Gessani S, Julkunen I, et al. Identification of distinct signaling pathways leading to the phosphorylation of interferon regulatory factor 3. J Biol Chem 2001;276:355–63.PubMedCrossRef Servant MJ, ten Oever B, LePage C, Conti L, Gessani S, Julkunen I, et al. Identification of distinct signaling pathways leading to the phosphorylation of interferon regulatory factor 3. J Biol Chem 2001;276:355–63.PubMedCrossRef
16.
go back to reference Cerny A, Chisari FV. Pathogenesis of hepatitis C: immunological features of hepatic injury and viral persistence. Hepatology 1999;30:595–601.PubMedCrossRef Cerny A, Chisari FV. Pathogenesis of hepatitis C: immunological features of hepatic injury and viral persistence. Hepatology 1999;30:595–601.PubMedCrossRef
17.
go back to reference Disson O, Haouji D, Desagher S, Loesch K, Hahne M, Kremer EJ, et al. Impaired clearance of virus-infected hepatocytes in transgenic mice expressing the hepatitis C virus polyprotein. Gastroenterology 2004;126:859–72.PubMedCrossRef Disson O, Haouji D, Desagher S, Loesch K, Hahne M, Kremer EJ, et al. Impaired clearance of virus-infected hepatocytes in transgenic mice expressing the hepatitis C virus polyprotein. Gastroenterology 2004;126:859–72.PubMedCrossRef
18.
go back to reference Keskinen P, Nyqvist M, Sareneva T, Pirhonen J, Melen K, Julkunen I. Impaired antiviral response in human hepatoma cells. Virology 1999;263:364–75.PubMedCrossRef Keskinen P, Nyqvist M, Sareneva T, Pirhonen J, Melen K, Julkunen I. Impaired antiviral response in human hepatoma cells. Virology 1999;263:364–75.PubMedCrossRef
19.
go back to reference Foy E, Li K, Wang C, Sumpter R Jr, Ikeda M, Lemon SM, et al. Regulation of interferon regulatory factor-3 by hepatitis C virus serine protease. Science 2003;300:1145–8.PubMedCrossRef Foy E, Li K, Wang C, Sumpter R Jr, Ikeda M, Lemon SM, et al. Regulation of interferon regulatory factor-3 by hepatitis C virus serine protease. Science 2003;300:1145–8.PubMedCrossRef
20.
go back to reference Otsuka M, Kato N, Moriyama M, Taniguchi H, Wang Y, Dharel N, et al. Interaction between the HCV NS3 protein and the host TBK1 protein leads to inhibiton of cellular antiviral responses. Hepatology 2005;41:1004–12.PubMedCrossRef Otsuka M, Kato N, Moriyama M, Taniguchi H, Wang Y, Dharel N, et al. Interaction between the HCV NS3 protein and the host TBK1 protein leads to inhibiton of cellular antiviral responses. Hepatology 2005;41:1004–12.PubMedCrossRef
21.
go back to reference Kato N, Yoshida H, Ono-Nita SK, Kato J, Goto T, Otsuka M, et al. Activation of intracellular signaling by hepatitis B and C viruses: C-viral core is the most potent signal inducer. Hepatology 2000;32:405–12.PubMedCrossRef Kato N, Yoshida H, Ono-Nita SK, Kato J, Goto T, Otsuka M, et al. Activation of intracellular signaling by hepatitis B and C viruses: C-viral core is the most potent signal inducer. Hepatology 2000;32:405–12.PubMedCrossRef
22.
go back to reference Qin W, Yamashita T, Shirota Y, Ling Y, Wei W, Murakami S. Mutational analysis of the structure and functions of hepatitis C virus RNA-dependent RNA polymerase. Hepatology 2001;33:728–37.PubMedCrossRef Qin W, Yamashita T, Shirota Y, Ling Y, Wei W, Murakami S. Mutational analysis of the structure and functions of hepatitis C virus RNA-dependent RNA polymerase. Hepatology 2001;33:728–37.PubMedCrossRef
23.
go back to reference Vo NM, Oh JW, Lai MMC. Identification of RNA ligands that bind hepatitis C virus polymerase selectively and inhibit its RNA synthesis from the natural viral RNA templates. Virology 2003;307:301–16.PubMedCrossRef Vo NM, Oh JW, Lai MMC. Identification of RNA ligands that bind hepatitis C virus polymerase selectively and inhibit its RNA synthesis from the natural viral RNA templates. Virology 2003;307:301–16.PubMedCrossRef
24.
go back to reference Lohmann V, Ross A, Körner F, Koch JO, Bartenshlager R. Biochemical and kinetic analysis of NS5B RNA-dependent RNA polymerase of the hepatitis C virus. Virology 1998;249:108–18.PubMedCrossRef Lohmann V, Ross A, Körner F, Koch JO, Bartenshlager R. Biochemical and kinetic analysis of NS5B RNA-dependent RNA polymerase of the hepatitis C virus. Virology 1998;249:108–18.PubMedCrossRef
25.
go back to reference Oh JW, Ito T, Lai MM. A recombinant hepatitis C virus RNA-dependent RNA polymerase capable of copying the full length viral RNA. J Virol 1999;73:7694–702.PubMed Oh JW, Ito T, Lai MM. A recombinant hepatitis C virus RNA-dependent RNA polymerase capable of copying the full length viral RNA. J Virol 1999;73:7694–702.PubMed
26.
go back to reference Zhong W, Ferrari E, Lesburg CA, Maag D, Ghosh SK, Cameron CE,et al. Template/primer requirements and single nucleotide incorporation by hepatitis C virus nonstructural protein 5B polymerase. J Virol 2000;74:9134–43.PubMedCrossRef Zhong W, Ferrari E, Lesburg CA, Maag D, Ghosh SK, Cameron CE,et al. Template/primer requirements and single nucleotide incorporation by hepatitis C virus nonstructural protein 5B polymerase. J Virol 2000;74:9134–43.PubMedCrossRef
27.
go back to reference Mottola G, Cardinali G, Ceccacci A, Trozzi C, Batholomew L, Torrisi MR, et al. Hepatitis C virus nonstructural proteins are localized in a modified endoplasmic reticulum of cells expressing viral subgenomic replicons. Virology 2002;293:31–43.PubMedCrossRef Mottola G, Cardinali G, Ceccacci A, Trozzi C, Batholomew L, Torrisi MR, et al. Hepatitis C virus nonstructural proteins are localized in a modified endoplasmic reticulum of cells expressing viral subgenomic replicons. Virology 2002;293:31–43.PubMedCrossRef
28.
go back to reference Dimitrova M, Imbert I, Kieny MP, Schuster C. Protein-protein interactions between hepatitis C virus nonstructural proteins. J Virol 2003;77:5401–14.PubMedCrossRef Dimitrova M, Imbert I, Kieny MP, Schuster C. Protein-protein interactions between hepatitis C virus nonstructural proteins. J Virol 2003;77:5401–14.PubMedCrossRef
29.
go back to reference Shirota Y, Luo H, Qin W, Kaneko S, Yamashita T, Kobayashi K, et al. Hepatitis C virus (HCV) NS5A binds RNA-dependent RNA polymerase (RdRp) NS5B and modulates RNA-dependent RNA polymerase activity. J Biol Chem 2002;277:11149–55.PubMedCrossRef Shirota Y, Luo H, Qin W, Kaneko S, Yamashita T, Kobayashi K, et al. Hepatitis C virus (HCV) NS5A binds RNA-dependent RNA polymerase (RdRp) NS5B and modulates RNA-dependent RNA polymerase activity. J Biol Chem 2002;277:11149–55.PubMedCrossRef
30.
go back to reference Shimakami T, Hijikata M, Luo H, Ma YY, Kaneko S, Shimotohno K, et al. Effect of interaction between hepatitis C virus NS5A and NS5B on hepatitis C virus RNA replication with the hepatitis C virus replicon. J Virol 2004;78:2738–48.PubMedCrossRef Shimakami T, Hijikata M, Luo H, Ma YY, Kaneko S, Shimotohno K, et al. Effect of interaction between hepatitis C virus NS5A and NS5B on hepatitis C virus RNA replication with the hepatitis C virus replicon. J Virol 2004;78:2738–48.PubMedCrossRef
31.
go back to reference Lohmann V, Körner F, Koch JO, Herian U, Theilmann L, Bartenshlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999;285:110–3.PubMedCrossRef Lohmann V, Körner F, Koch JO, Herian U, Theilmann L, Bartenshlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999;285:110–3.PubMedCrossRef
32.
go back to reference Lohmann V, Körner F, Dobeierzewska A, Bartenshlager R. Mutations in hepatitis C virus RNAs conferring cell culture adaptation. J Virol 2001;75:1437–49.PubMedCrossRef Lohmann V, Körner F, Dobeierzewska A, Bartenshlager R. Mutations in hepatitis C virus RNAs conferring cell culture adaptation. J Virol 2001;75:1437–49.PubMedCrossRef
Metadata
Title
Interferon-beta is activated by hepatitis C virus NS5B and inhibited by NS4A, NS4B, and NS5A
Authors
Masaru Moriyama
Naoya Kato
Motoyuki Otsuka
Run-Xuan Shao
Hiroyoshi Taniguchi
Takao Kawabe
Masao Omata
Publication date
01-06-2007
Publisher
Springer-Verlag
Published in
Hepatology International / Issue 2/2007
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-007-9003-8

Other articles of this Issue 2/2007

Hepatology International 2/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.